Immunomodulation by ionizing radiation—impact for design of radio-immunotherapies and for treatment of inflammatory diseases

Immunological Reviews

Volumn 280, Issue 1, 2017, Pages 231-248

  Frey, Benjamin ^a   Rückert, Michael ^a   Deloch, Lisa ^a   Rühle, Paul F ^a   Derer, Anja ^a   Fietkau, Rainer ^a   Gaipl, Udo S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

immunogenic cancer cell death; immunomonitoring; in situ vaccination; inflammation; ionizing radiation; radio immunotherapy

Indexed keywords

APOPTOSIS INHIBITOR; LIPOCORTIN 5; PHOSPHATIDYLSERINE; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER PROGNOSIS; CELL DEATH; CELL INFILTRATION; CELL SURFACE; ELECTROMAGNETIC RADIATION; FLOW CYTOMETRY; FRACTIONATION; HYDROSTATIC PRESSURE; HYPERTHERMIA; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; IONIZING RADIATION; LIQUID BIOPSY; PARTICLE RADIATION; PRIORITY JOURNAL; PROTEIN BINDING; RADIATION DOSE; RADIOIMMUNOLOGY; RADIOIMMUNOTHERAPY; REVIEW; TISSUE INJURY; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINATION; ANIMAL; HUMAN; IMMUNITY; IMMUNOLOGY; IMMUNOPATHOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES;

ANIMALS; CELL DEATH; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION, IONIZING; RADIOIMMUNOTHERAPY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 85031119484     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12572     Document Type: Review

References (210)

1. Jaffray DA. Image-guided radiotherapy: From current concept to future perspectives. Nat Rev Clin Oncol. 2012;9:688-699.
2. Kadhim MA, Hill MA. Non-targeted effects of radiation exposure: Recent advances and implications. Radiat Prot Dosimetry. 2015;166:118-124.
3. Frey B, Hehlgans S, Rodel F, Gaipl US. Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases. Cancer Lett. 2015;368:230-237.
4. Zhang D, Zhou T, He F, et al. Reactive oxygen species formation and bystander effects in gradient irradiation on human breast cancer cells. Oncotarget. 2016;7:41622-41636.
5. Fernandez-Gonzalo R, Baatout S, Moreels M. Impact of particle irradiation on the immune system: From the clinic to mars. Front Immunol. 2017;8:177.
6. Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12.
7. Rühle P. Development of Flow Cytometry-Bases Assys for Detailed Immune Monitoring and Their Application for Patients Exposed to Radiation. Doctoral Thesis. Naturwissenschaftliche Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen. 2016:1-149.
8. Balagamwala EH, Stockham A, Macklis R, Singh AD. Introduction to radiotherapy and standard teletherapy techniques. Dev Ophthalmol. 2013;52:1-14.
9. Pinto MM, Santos NF, Amaral A. Current status of biodosimetry based on standard cytogenetic methods. Radiat Environ Biophys. 2010;49:567-581.
10. Sihver L, Ploc O, Puchalska M, et al. Radiation environment at aviation altitudes and in space. Radiat Prot Dosimetry. 2015;164:477-483.
11. Orth M, Lauber K, Niyazi M, et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys. 2014;53:1-29.
12. Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US. Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol. 2016;6:141.
13. Heylmann D, Rodel F, Kindler T, Kaina B. Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. Biochem Biophys Acta. 2014;1846:121-129.
14. Belka C, Ottinger H, Kreuzfelder E, et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol. 1999;50:199-204.
15. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal. 2011;14:1315-1335.
16. Nikitaki Z, Nikolov V, Mavragani IV, et al. Measurement of complex DNA damage induction and repair in human cellular systems after exposure to ionizing radiations of varying linear energy transfer (LET). Free Radical Res. 2016;50:S64-s78.
17. Aziz K, Nowsheen S, Pantelias G, Iliakis G, Gorgoulis VG, Georgakilas AG. Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy. Pharmacol Ther. 2012;133:334-350.
18. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107-120.
19. Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol. 2012;2:116.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.
21. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780-783.
22. Yan D, Sherman JH, Keidar M. Cold atmospheric plasma, a novel promising anti-cancer treatment modality. Oncotarget. 2016;8:15977-15995.
23. Klammer H, Mladenov E, Li F, Iliakis G. Bystander effects as manifestation of intercellular communication of DNA damage and of the cellular oxidative status. Cancer Lett. 2015;356:58-71.
24. Nikitaki Z, Mavragani IV, Laskaratou DA, et al. Systemic mechanisms and effects of ionizing radiation: A new ‘old’ paradigm of how the bystanders and distant can become the players. Semin Cancer Biol. 2016;37–38:77-95.
25. Frey B, Rubner Y, Kulzer L, et al. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2014;63:29-36.
26. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862-870.
27. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev Clin Oncol. 2017;14:365-379.
28. Matzinger P. The danger model: A renewed sense of self. Science. 2002;296:301-305.
29. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
30. Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: The yin and yang effects. Nat Rev Clin Oncol. 2016;13:611-626.
31. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170:6338-6347.
32. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403-416.
33. Garrido F, Ruiz-Cabello F, Aptsiauri N. Rejection versus escape: The tumor MHC dilemma. Cancer Immunol Immunother. 2017;66:259-271.
34. Gehrmann M, Radons J, Molls M, Multhoff G. The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones. 2008;13:1-10.
35. Multhoff G, Botzler C, Wiesnet M, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer. 1995;61:272-279.
36. Botzler C, Issels R, Multhoff G. Heat-shock protein 72 cell-surface expression on human lung carcinoma cells in associated with an increased sensitivity to lysis mediated by adherent natural killer cells. Cancer Immunol Immunother. 1996;43:226-230.
37. Specht HM, Ahrens N, Blankenstein C, et al. Heat shock protein 70 (Hsp70) peptide activated natural killer (NK) cells for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCTx) – From preclinical studies to a clinical phase II trial. Front Immunol. 2015;6:162.
38. Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:293-301.
39. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
40. Arnold-Schild D, Hanau D, Spehner D, et al. Cutting edge: Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999;162:3757-3760.
41. Multhoff G. Activation of natural killer cells by heat shock protein 70. 2002. Int J Hyperth. 2009;25:169-175.
42. Botzler C, Li G, Issels RD, Multhoff G. Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response. Cell Stress Chaperones. 1998;3:6-11.
43. Schildkopf P, Frey B, Ott OJ, et al. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol. 2011;101:109-115.
44. Matsumura S, Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res. 2010;173:418-425.
45. + T cells. Mol Ther. 2010;18:912-920.
46. Schildkopf P, Holmer R, Sieber R, et al. Hyperthermia in combination with X-irradiation induces inflammatory forms of cell death. Autoimmunity. 2009;42:311-313.
47. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259-1271.
48. Frey B, Weiss EM, Rubner Y, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperth. 2012;28:528-542.
49. Datta NR, Ordonez SG, Gaipl US, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. Cancer Treat Rev. 2015;41:742-753.
50. Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA. 2011;108:9851-9856.
51. Schildkopf P, Ott OJ, Frey B, et al. Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments. Curr Med Chem. 2010;17:3045-3057.
52. Mantel F, Frey B, Haslinger S, et al. Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther Onkol. 2010;186:587-599.
53. Munoz LE, Frey B, Pausch F, et al. The role of annexin A5 in the modulation of the immune response against dying and dead cells. Curr Med Chem. 2007;14:271-277.
54. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3-12.
55. Schildkopf P, Frey B, Mantel F, et al. Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells. Biochem Biophys Res Comm. 2010;391:1014-1020.
56. Werthmoller N, Frey B, Ruckert M, Lotter M, Fietkau R, Gaipl US. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo. Int J Hyperth. 2016;32:23-30.
57. Parker KH, Horn LA, Ostrand-Rosenberg S. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. J Leukoc Biol. 2016;100:463-470.
58. Werthmoller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis. 2015;6:e1761.
59. Datta NR, Grobholz R, Puric E, et al. Enhanced tumour regression in a patient of liposarcoma treated with radiotherapy and hyperthermia: Hint for dynamic immunomodulation by hyperthermia. Int J Hyperth. 2015;31:574-577.
60. Trefna HD, Crezee H, Schmidt M, et al. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. Int J Hyperth. 2017;31:1-12.
61. Dobsicek Trefna H, Crezee J, Schmidt M, et al. Quality assurance guidelines for superficial hyperthermia clinical trials: II. Technical requirements for heating devices. Strahlenther Onkol. 2017;193:351-366.
62. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97-111.
63. Suzuki Y, Mimura K, Yoshimoto Y, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Can Res. 2012;72:3967-3976.
64. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.
65. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482-491.
66. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.
67. Vandenberk L, Garg AD, Verschuere T, et al. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology. 2016;5:e1083669.
68. Frey B, Gaipl US. The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. Semin Immunopathol. 2011;33:497-516.
69. Frey B, Schildkopf P, Rodel F, et al. AnnexinA5 renders dead tumor cells immunogenic–implications for multimodal cancer therapies. J Immunotoxicol. 2009;6:209-216.
70. Bondanza A, Zimmermann VS, Rovere-Querini P, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med. 2004;200:1157-1165.
71. Frey B, Munoz LE, Pausch F, et al. The immune reaction against allogeneic necrotic cells is reduced in Annexin A5 knock out mice whose macrophages display an anti-inflammatory phenotype. J Cell Mol Med. 2009;13:1391-1399.
72. Schilling D, Gehrmann M, Steinem C, et al. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J. 2009;23:2467-2477.
73. van Tilborg GA, Vucic E, Strijkers GJ, et al. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem. 2010;21:1794-1803.
74. Riedl S, Rinner B, Asslaber M, et al. In search of a novel target – Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochem Biophys Acta. 2011;1808:2638-2645.
75. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci. 2005;62:971-988.
76. Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis. 2010;15:1072-1082.
77. Rosenbaum S, Kreft S, Etich J, et al. Identification of novel binding partners (annexins) for the cell death signal phosphatidylserine and definition of their recognition motif. J Biol Chem. 2011;286:5708-5716.
78. Belhocine TZ, Blankenberg FG, Kartachova MS, et al. (99 m)Tc-Annexin A5 quantification of apoptotic tumor response: A systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging. 2015;42:2083-2097.
79. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
80. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
81. Tureci O, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res. 2016;22:1885-1896.
82. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788-792.
83. Baird JR, Friedman D, Cottam B, et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Can Res. 2016;76:50-61.
84. Kulzer L, Rubner Y, Deloch L, et al. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol. 2014;11:328-336.
85. Becht E, Giraldo NA, Germain C, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol. 2016;130:95-190.
86. Fridman WH, Remark R, Goc J, et al. The immune microenvironment: A major player in human cancers. Int Arch Allergy Immunol. 2014;164:13-26.
87. Balermpas P, Michel Y, Wagenblast J, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110:501-509.
88. Balermpas P, Rodel F, Rodel C, et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2016;138:171-181.
89. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344:641-645.
90. Frey B, Ruckert M, Weber J, et al. Hypofractionated irradiation has immune stimulatory potential and induces a timely restricted infiltration of immune cells in colon cancer tumors. Front Immunol. 2017;8:231.
91. Finkel P, Frey B, Mayer F, et al. The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology. 2016;5:e1101206.
92. Crouse J, Bedenikovic G, Wiesel M, et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity. 2014;40:961-973.
93. Frey B, Derer A, Scheithauer H, Wunderlich R, Fietkau R, Gaipl US. Cancer cell death-inducing radiotherapy: Impact on local tumour control, tumour cell proliferation and induction of systemic anti-tumour immunity. Adv Exp Med Biol. 2016;930:151-172.
94. Wennerberg E, Lhuillier C, Vanpouille-Box C, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:229.
95. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93:892-899.
96. Rodel F, Frey B, Capalbo G, et al. Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF-kappaB activation and mediates the anti-inflammatory properties of low-dose ionising-radiation. Radiother Oncol. 2010;97:346-351.
97. Drabsch Y, ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia. 2011;16:97-108.
98. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183-194.
99. Zhang F, Wang H, Wang X, et al. TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget. 2016;7:52294-52306.
100. Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Can Res. 2015;75:2232-2242.
101. Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 2010;24:1637-1643.
102. Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Can Res. 2008;68:5432-5438.
103. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242.
104. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
105. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-5074.
106. Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950.
107. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
108. Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine. 2017;96:e6369.
109. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
110. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-695.
111. Derer A, Spiljar M, Baumler M, et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol. 2016;7:610.
112. Gong X, Li X, Jiang T, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances anti-tumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12:1085-1097.
113. Hartmann J, Wolfelschneider J, Stache C, et al. Novel technique for high-precision stereotactic irradiation of mouse brains. Strahlenther Onkol. 2016;192:806-814.
114. Stache C, Bils C, Fahlbusch R, et al. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin. Neurosurg Focus. 2016;41:E14.
115. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015;51:221-228.
116. Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36:587-595.
117. Qu QX, Huang Q, Shen Y, Zhu YB, Zhang XG. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer. Tumour Biol. 2016;37:5031-5037.
118. Frey B, Stache C, Rubner Y, et al. Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. J Immunotoxicol. 2012;9:301-313.
119. Teng F, Meng X, Kong L, et al. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl Res. 2015;166(721–732):e721.
120. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014-1022.
121. Sharma A, Bode B, Wenger RH, et al. gamma-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE. 2011;6:e28217.
122. Gunther S, Ostheimer C, Stangl S, et al. Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer. Front Immunol. 2015;6:556.
123. Multhoff G, Pockley AG, Streffer C, Gaipl US. Dual role of heat shock proteins (HSPs) in anti-tumor immunity. Curr Mol Med. 2012;12:1174-1182.
124. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84:879-880.
125. Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: Rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. 2016;65:779-786.
126. Ebner DK, Tinganelli W, Helm A, et al. The immunoregulatory potential of particle radiation in cancer therapy. Front Immunol. 2017;8:99.
127. Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. 2015;33:7415-7422.
128. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: Overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16:219-233.
129. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. Cancer J Clin. 2017;67:65-85.
130. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782-795.
131. Carstens JL, Correa de Sampaio P, Yang D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095.
132. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Can Res. 2007;67:9518-9527.
133. Yamamoto Y, Offord CP, Kimura G, et al. Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Br J Cancer. 2016;115:195-202.
134. Hettich M, Lahoti J, Prasad S, Niedermann G. Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing gamma-irradiation. Can Res. 2016;76:4673-4683.
135. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589-602.
136. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Can Res. 2002;62:1462-1470.
137. Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the game in immunotherapy. Trends Cancer. 2016;2:286-294.
138. Walshaw RC, Honeychurch J, Illidge TM. Stereotactic ablative radiotherapy and immunotherapy combinations: Turning the future into systemic therapy? Br J Radiol. 2016;89:20160472.
139. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343-349.
140. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379-5388.
141. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Can Res. 2011;71:2488-2496.
142. Lucarini V, Buccione C, Ziccheddu G, et al. Combining type I interferons and 5-aza-2′-deoxycitidine to improve anti-tumor response against melanoma. J Invest Dermatol. 2017;137:159-169.
143. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood. 2009;114:589-595.
144. Keisari Y. Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation. Front Biosci. 2017;22:310-347.
145. Marabelle A, Filatenkov A, Sagiv-Barfi I, Kohrt H. Radiotherapy and toll-like receptor agonists. Semin Radiat Oncol. 2015;25:34-39.
146. Levy A, Chargari C, Marabelle A, Perfettini JL, Magne N, Deutsch E. Can immunostimulatory agents enhance the abscopal effect of radiotherapy? Eur J Cancer. 2016;62:36-45.
147. Frey B, Rubner Y, Wunderlich R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation – Implications for cancer therapies. Curr Med Chem. 2012;19:1751-1764.
148. Riley LB, Agarwala SS. Melanoma vaccines. Exp Rev Vaccines. 2008;7:937-949.
149. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351-360.
150. Jaroslawski S, Toumi M. Sipuleucel-T (Provenge((R)))-autopsy of an innovative paradigm change in cancer treatment: Why a single-product biotech company failed to capitalize on its breakthrough invention. BioDrugs. 2015;29:301-307.
151. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial. Lancet Oncol. 2015;16:795-803.
152. Mondini M, Nizard M, Tran T, et al. Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther. 2015;14:1336-1345.
153. Seledtsov VI, Goncharov AG, Seledtsova GV. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Human Vaccin Immunother. 2015;11:851-869.
154. Yamamoto K. Food processing by high hydrostatic pressure. Biosci Biotechnol Biochem. 2017;81:672-679.
155. Gross M, Jaenicke R. Proteins under pressure. The influence of high hydrostatic pressure on structure, function and assembly of proteins and protein complexes. Eur J Biochem. 1994;221:617-630.
156. Frey B, Janko C, Ebel N, et al. Cells under pressure – Treatment of eukaryotic cells with high hydrostatic pressure, from physiologic aspects to pressure induced cell death. Curr Med Chem. 2008;15:2329-2336.
157. Frey B, Franz S, Sheriff A, et al. Hydrostatic pressure induced death of mammalian cells engages pathways related to apoptosis or necrosis. Cell Mol Biol. 2004;50:459-467.
158. Korn A, Frey B, Sheriff A, et al. High hydrostatic pressure inactivated human tumour cells preserve their immunogenicity. Cell Mol Biol. 2004;50:469-477.
159. Weiss EM, Meister S, Janko C, et al. High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. J Immunotoxicol. 2010;7:194-204.
160. Weiss EM, Wunderlich R, Ebel N, et al. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol. 2012;2:132.
161. Fucikova J, Moserova I, Truxova I, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135:1165-1177.
162. Mikyskova R, Stepanek I, Indrova M, et al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol. 2016;48:953-964.
163. Urbanova L, Hradilova N, Moserova I, et al. High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy. Immunol Lett. 2017;187:27-34.
164. Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. 2015;6:663.
165. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science. 2013;339:286-291.
166. Schmid-Monnard C. Über Heilung des Gelenkrheumatismus durch Röntgenstrahlung bei Kindern. Fortschr Röntgenstr. 1898;1:209.
167. Reichl B, Block A, Schafer U, et al. DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: Physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol. 2015;191:701-709.
168. Rodel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. Int J Radiat Biol. 2007;83:357-366.
169. Rodel F, Frey B, Gaipl U, et al. Modulation of inflammatory immune reactions by low-dose ionizing radiation: Molecular mechanisms and clinical application. Curr Med Chem. 2012;19:1741-1750.
170. Wunderlich R, Ruehle PF, Deloch L, et al. Interconnection between DNA damage, senescence, inflammation, and cancer. Front Biosci. 2017;22:348-369.
171. Rodel F, Frey B, Manda K, et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol. 2012;2:120.
172. Valledor AF, Comalada M, Santamaria-Babi LF, Lloberas J, Celada A. Macrophage proinflammatory activation and deactivation: A question of balance. Adv Immunol. 2010;108:1-20.
173. Wunderlich R, Ernst A, Rodel F, et al. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol. 2015;179:50-61.
174. Frischholz B, Wunderlich R, Ruhle PF, et al. Reduced secretion of the inflammatory cytokine IL-1beta by stimulated peritoneal macrophages of radiosensitive Balb/c mice after exposure to 0.5 or 0.7 Gy of ionizing radiation. Autoimmunity. 2013;46:323-328.
175. Lodermann B, Wunderlich R, Frey S, et al. Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-1beta by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol. 2012;88:727-734.
176. Schaue D, Jahns J, Hildebrandt G, Trott KR. Radiation treatment of acute inflammation in mice. Int J Radiat Biol. 2005;81:657-667.
177. Schaue D, Marples B, Trott KR. The effects of low-dose X-irradiation on the oxidative burst in stimulated macrophages. Int J Radiat Biol. 2002;78:567-576.
178. Large M, Reichert S, Hehlgans S, Fournier C, Rodel C, Rodel F. A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. Radiat Oncol. 2014;9:80.
179. Jelonek K, Pietrowska M, Widlak P. Systemic effects of ionizing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: The influence of inflammation and radiation toxicity. Int J Radiat Biol. 2017;93:683-696.
180. Rodel F, Fournier C, Wiedemann J, et al. Basics of radiation biology when treating hyperproliferative benign diseases. Front Immunol. 2017;8:519.
181. Ott OJ, Hertel S, Gaipl US, Frey B, Schmidt M, Fietkau R. The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome. Long-term results. Strahlenther Onkol. 2014;190:293-297.
182. Ott OJ, Hertel S, Gaipl US, Frey B, Schmidt M, Fietkau R. The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome. Long-term results. Strahlenther Onkol. 2014;190:394-398.
183. Ott OJ, Jeremias C, Gaipl US, Frey B, Schmidt M, Fietkau R. Radiotherapy for benign achillodynia. Long-term results of the Erlangen Dose Optimization Trial. Strahlenther Onkol. 2015;191:979-984.
184. Ott OJ, Jeremias C, Gaipl US, Frey B, Schmidt M, Fietkau R. Radiotherapy for benign calcaneodynia: Long-term results of the Erlangen Dose Optimization (EDO) trial. Strahlenther Onkol. 2014;190:671-675.
185. Deloch L. The Impact of Low-Dose Irradiation on Attenuation of Inflammation and Bone Metabolism – Osteoimmunological Analyses with hTNF-α tg and C57Bl/6 Mice as a Model System doctoral thesis. Doctoral Thesis. Naturwissenschaftliche Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen. 2017.
186. Deetjen P, Falkenbach A, Harder D, Jöckel H, Kaul A, von Philipsborn H. Radon als Heilmittel, Therapeutische Wirksamkeit, biologischer Wirkungsmechanismus und vergleichende Risikobewertung. Hamburg: Verlag Dr. Kovac; 2005.
187. Janiak MK, Wincenciak M, Cheda A, Nowosielska EM, Calabrese EJ. Cancer immunotherapy: How low-level ionizing radiation can play a key role. Cancer Immunol Immunother. 2017;66:819-832.
188. Ruhle PF, Fietkau R, Gaipl US, Frey B. Development of a modular assay for detailed immunophenotyping of peripheral human whole blood samples by multicolor flow cytometry. Int J Mol Sci. 2016;17:1-29.
189. Candeias SM, Gaipl US. The immune system in cancer prevention, development and therapy. Anticancer Agents Med Chem. 2016;16:101-107.
190. Galon J, Pages F, Marincola FM, et al. Cancer classification using the immunoscore: A worldwide task force. J Transl Med. 2012;10:205.
191. Karakhanova S, Ryschich E, Mosl B, et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer. 2015;112:1027-1036.
192. Quandt D, Zucht HD, Amann A, et al. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget. 2017;8:48507-48520.
193. Bjoern J, Brimnes MK, Andersen MH, Thor Straten P, Svane IM. Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2. Scand J Immunol. 2011;73:222-233.
194. Chattopadhyay PK, Roederer M. Cytometry: Today's technology and tomorrow's horizons. Methods. 2012;57:251-258.
195. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12:191-200.
196. Giraldo NA, Becht E, Vano Y, et al. Tumor-infiltrating and peripheral blood T cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23:4416-4428.
197. Munoz LE, Janko C, Grossmayer GE, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1733-1742.
198. Gaipl US, Munoz LE, Grossmayer G, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun. 2007;28:114-121.
199. Bernier J. Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing. Crit Rev Oncol Hematol. 2016;108:97-108.
200. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): A curative approach? Nat Rev Clin Oncol. 2016;13:516-524.
201. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Can Res. 2014;74:5458-5468.
202. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: A synergistic combination. J Clin Invest. 2013;123:2756-2763.
203. Balermpas P, Rodel F, Krause M, et al. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer. 2017;141:594-603.
204. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28:285-295.
205. Moskovitz JM, Moy J, Seiwert TY, Ferris RL. Immunotherapy for head and neck squamous cell carcinoma: A review of current and emerging therapeutic options. Oncologist. 2017;22:680-693.
206. Ward MJ, Thirdborough SM, Mellows T, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110:489-500.
207. Weber M, Moebius P, Buttner-Herold M, et al. Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas–an immunohistochemical study. Br J Cancer. 2015;113:510-519.
208. Skinner HD, Giri U, Yang LP, et al. Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. 2017;23:2713-2722.
209. Frey B, Gaipl US. Radio-immunotherapy: The focused beam expands. Lancet Oncol. 2015;16:742-743.
210. Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6:e10.